Skip to main content

Advertisement

SpringerLink
Log in

The Role of ARV Associated Adverse Drug Reactions in Influencing Adherence Among HIV-Infected Individuals: A Systematic Review and Qualitative Meta-Synthesis

  • Substantive Review
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

Poor adherence remains a major barrier to achieving the clinical and public health benefits of antiretroviral drugs (ARVs). A systematic review and qualitative meta-synthesis was conduct to evaluate how ARV adverse drug reactions may influence ARV adherence. Thirty-nine articles were identified, and 33 reported that ARV adverse drug reactions decreased adherence and six studies found no influence. Visually noticeable adverse drug reactions and psychological adverse reactions were reported as more likely to cause non-adherence compared to other adverse drug reactions. Six studies reported a range of adverse reactions associated with EFV-containing regimens contributing to decreased adherence. Informing HIV-infected individuals about ARV adverse drug reactions prior to initiation, counselling about coping mechanisms, and experiencing the effectiveness of ARVs on wellbeing may improve ARV adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. UNAIDS. UNAIDS FACT SHEET 2014. http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet. Accessed 15 May 2015.

  2. Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, Li PCK, Kantipong P, et al. HIV-1 drug resistance mutations among Antiretroviral-Naı¨ve HIV-1 infected patients in Asia: results from the TREAT Asia studies to evaluate resistance-monitoring study. Clinical Infect Dis. 2011;52:1053–7.

    Article  CAS  Google Scholar 

  3. WHO, UNICEF, UNAIDS. Global update on HIV treatment 2013: results, impact and opportunities summary. http://www.who.int/hiv/pub/progressreports/update2013/en/. Accessed 7 July 2015.

  4. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2014. http://www.who.int/hiv/pub/guidelines/keypopulations/en/. Accessed 12 May 2015.

  5. Veloso VG, Velasque LS, Grinsztejn B, Torres TS, Cardoso SW. Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age. Braz J infect dis. 2014;18:34–41.

    Article  PubMed  Google Scholar 

  6. WHO. Surveillance of antiretroviral drug toxicity during pregnancy and breastfeeding. Geneva, World Health Organization 2013. http://apps.who.int/iris/handle/10665/91768?mode=full. Accessed 9 June 2015.

  7. Nadkar MY, Bajpai S. Antiretroviral therapy: toxicity and adherence. JAPI. 2009;57:375–6.

    PubMed  Google Scholar 

  8. Moher D, Liberati A, Tetzlaff J, Altman D, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e100009.

    Article  Google Scholar 

  9. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012;12:181.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Noyes JSL. Supplemental guidance on selecting a method of qualitative evidence synthesis, and integrating qualitative evidence with Cochrane intervention reviews. In: Noyes J, Booth A, Hannes K, editors. Supplementary guidance for inclusion of qualitative research in Cochrane systematic reviews of interventions. Oxford: Cochrane Collaboration Qualitative Methods Group; 2011.

    Google Scholar 

  11. Critical Appraisal Skills Programme. CASP Qualitative Checklist, 2006. http://media.wix.com/ugd/dded87_951541699e9edc71ce66c9bac4734c69.pdf. Accessed 5 March 2015.

  12. Monroe AK, Rowe TL, Moore RD, Chander G. Medication adherence in HIV-positive patients with diabetes or hypertension: a focus group study. BMC Health Serv Res. 2013;13:488.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, et al. Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med. 2015;12:e1001895.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8:45.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Laws MB, Wilson IB, Bowser DM, Kerr SE. Taking antiretroviral therapy for HIV infection: learning from patients’ stories. J Gen Intern Med. 2000;15:848–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Siegel K, Lekas HM, Schrimshaw EW, Johnson JK. Factors associated with HIV-infected women’s use or intention to use AZT during pregnancy. AIDS Educ Prev. 2001;13:189–206.

    Article  CAS  PubMed  Google Scholar 

  17. Pugatch D, Bennett L, Patterson D. HIV medication adherence in adolescents: a qualitative study. J HIV/AIDS Prev Educ Adolesc Child. 2002;5:9–29.

    Article  Google Scholar 

  18. Witteveen E, Van Ameijden EJC. Drug users and HIV-combination therapy (HAART): factors which impede or facilitate adherence. Subst Use Misuse. 2002;37:1905–25.

    Article  PubMed  Google Scholar 

  19. Abel E, Painter L. Factors that influence adherence to HIV medications: perceptions of women and health care providers. J Assoc Nurses AIDS Care. 2003;14:61–9.

    Article  PubMed  Google Scholar 

  20. Powell-Cope GM, White J, Henkelman EJ, Turner BJ. Qualitative and quantitative assessments of HAART adherence of substance-abusing women. AIDS Care. 2003;15:239–49.

    Article  CAS  PubMed  Google Scholar 

  21. Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV + men and women in four US cities. AIDS Behav. 2003;7:61–72.

    Article  PubMed  Google Scholar 

  22. Westerfelt A. A qualitative investigation of adherence issues for men who are HIV positive. Soc Work. 2004;49:231–9.

    Article  PubMed  Google Scholar 

  23. Prutch PT. Understanding the nature of medication adherence issues with the HIV-infected patient in the family practice setting [Ph.D.]. Ann Arbor: Colorado State University; 2005:85-85.

  24. Roberts KJ. Barriers to antiretroviral medication adherence in young HIV-infected children. Youth Soc. 2005;37:230–45.

    Article  Google Scholar 

  25. Schrimshaw EW, Siegel K, Lekas HM. Changes in attitudes toward antiviral medication: a comparison of women living with HIV/AIDS in the pre-HAART and HAART eras. AIDS Behav. 2005;9:267–79.

    Article  PubMed  Google Scholar 

  26. Alfonso V, Bermbach N, Geller J, Montaner JS. Individual variability in barriers affecting people’s decision to take HAART: a qualitative study identifying barriers to being on HAART. AIDS Patient Care STDS. 2006;20:848–57.

    Article  PubMed  Google Scholar 

  27. Golub SA, Indyk D, Wainberg ML. Reframing HIV adherence as part of the experience of illness. Socl Work Health Care. 2006;42:167–88.

    Article  Google Scholar 

  28. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–65.

    Article  CAS  PubMed  Google Scholar 

  29. Beusterien KM, Davis EA, Flood R, Howard K, Jordan J. HIV patient insight on adhering to medication: a qualitative analysis. AIDS Care. 2008;20:251–9.

    Article  Google Scholar 

  30. Dahab M, Charalambous S, Hamilton R, Fielding K, Kielmann K, Churchyard GJ, et al. “That is why I stopped the ART”: patients’ & providers’ perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health. 2008;8:63.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chen WT, Shin CS, Simoni J, Fredriksen-Goldsen K, Zhang FJ, Starks H, et al. Attitudes toward antiretroviral therapy and complementary and alternative medicine in Chinese patients infected with HIV. J Assoc Nurses AIDS Care. 2009;20:203–17.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Vervoort SCJM, Grypdonck MHF, De Grauwe A, Hoepelman AIM, Borleffs JCC. Adherence to HAART: processes explaining adherence behavior in acceptors and non-acceptors. AIDS Care. 2009;21:431–8.

    Article  PubMed  Google Scholar 

  33. Curioso WH, Kepka D, Cabello R, Segura P, Kurth AE. Understanding the facilitators and barriers of antiretroviral adherence in Peru: a qualitative study. BMC Public Health. 2010;10:13.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Mimiaga MJ, Safren SA, Dvoryak S, Reisner SL, Needle R, Woody G. “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev. Ukraine. AIDS Care. 2010;22:1305–13.

    Article  PubMed  Google Scholar 

  35. Nsimba SED, Irunde H, Comoro C. Barriers to ARV adherence among HIV/AIDS positive persons taking anti-retroviral therapy in two Tanzanian regions 8–12 months after program initiation. J AIDS Clin Res. 2010;1:110–1.

    Article  Google Scholar 

  36. McDonald K, Kirkman M. HIV-positive women in Australia explain their use and non-use of antiretroviral therapy in preventing mother-to-child transmission. AIDS Care. 2011;23:578–84.

    Article  PubMed  Google Scholar 

  37. Musheke M, Bond V, Merten S. Individual and contextual factors influencing patient attrition from antiretroviral therapy care in an urban community of Lusaka. Zambia. J Int AIDS Soc. 2012;15(Suppl 1):1–9.

    PubMed  Google Scholar 

  38. Nyanzi-Wakholi B, Lara AM, Munderi P, Gilks C. The charms and challenges of antiretroviral therapy in Uganda: the DART experience. AIDS Care. 2012;24:137–42.

    PubMed  Google Scholar 

  39. Wasti SP, Simkhada P, Randall J, Freeman JV, Teijlingen EV. Factors influencing adherence to antiretroviral treatment in Nepal: a mixed-methods study. PLoS One. 2012;7:1–11.

    Article  Google Scholar 

  40. Wasti SP, Simkhada P, Randall J, Freeman JV, van Teijlingen E. Barriers to and facilitators of antiretroviral therapy adherence in Nepal: a qualitative study. J Health Popul Nutr. 2012;30:410–9.

    PubMed  PubMed Central  Google Scholar 

  41. Barnett W, Patten G, Kerschberger B, Conradie K, Garone DB, Van Cutsem G, et al. Perceived adherence barriers among patients failing second-line antiretroviral therapy in Khayelitsha, South Africa. S Afr J HIV Med. 2013;14:170–6.

    Article  Google Scholar 

  42. Lekhuleni ME, Mothiba TM, Maputle MS, Jali MN. Patients’ adherence to antiretroviral therapy at antiretroviral therapy sites in Limpopo Province, South Africa. Afr J Phys Health Educ Recreat Dance. 2013;19:75–85.

    Google Scholar 

  43. Vyankandondera J, Mitchell K, Asiimwe-Kateera B, Boer K, Mutwa P, Balinda JP, et al. Antiretroviral therapy drug adherence in Rwanda: perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care. 2013;25:1504–12.

    Article  PubMed  Google Scholar 

  44. Krummenacher I, Spencer B, Du Pasquier S, Bugnon O, Cavassini M, Schneider MP. Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme. Int J Clin Pharm. 2014;36:716–24.

    Article  PubMed  Google Scholar 

  45. Mattes D. “Life is not a rehearsal, it’s a performance”: an ethnographic enquiry into the subjectivities of children and adolescents living with antiretroviral treatment in Northeastern Tanzania. Child Youth Serv Rev. 2014;45:28–37.

    Article  Google Scholar 

  46. Peraza MC, Gonzalez I, Perez J. Factors related to antiretroviral therapy adherence in children and adolescents with HIV/AIDS in cuba. MEDICC Rev. 2015;17:35–40.

    Google Scholar 

  47. Brion JM, Menke EM. Perspectives Regarding Adherence to Prescribed Treatment in Highly Adherent HIV-Infected Gay Men. J Assoc Nurses AIDS Care. 2008;19:181–91.

    Article  PubMed  Google Scholar 

  48. Beckham S. Adherence to antiretroviral therapies in resource-poor settings: A mixed-methods case study in rural Tanzania [M.P.H.]. Ann Arbor: Yale University; 2009:108.

  49. Chen WT, Shiu CS, Yang JP, Simoni JM, Fredriksen-Goldsen KI, Lee TS, et al. Antiretroviral therapy (ART) Side effect impacted on quality of life, and depressive symptomatology: a mixed-method study. J AIDS Clin Res. 2013;4:218.

    PubMed  PubMed Central  Google Scholar 

  50. Mbonye M, Seeley J, Ssembajja F, Birungi J, Jaffar S. Adherence to antiretroviral therapy in Jinja, Uganda: a six-year follow-up study. PLoS One. 2013;8:e78243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM, Bimirew MA, Kassie DM. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia. PLoS One. 2014;9:e97353.

    Article  PubMed  PubMed Central  Google Scholar 

  52. McKinney O, Modeste NN, Lee JW, Gleason PC, Maynard-Tucker G. Determinants of antiretroviral therapy adherence among women in Southern Malawi: healthcare providers’ perspectives. AIDS Res Treat. 2014;2014:1–9.

    Article  Google Scholar 

  53. de Bonolo PF, César CC, Acúrcio FA, Ceccato MGB, de Pádua CAM, Álvares J, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005;19:S5–13.

    Article  Google Scholar 

  54. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15:38–44.

    Article  PubMed  Google Scholar 

  55. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy—self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808–16.

    Article  PubMed  Google Scholar 

  56. de Menezes Padua CA, Cesar CC, Bonolo PF, Acurcio FA, Guimaraes MDC. Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil. Braz J Infect Dis. 2007;11:20–6.

    Article  Google Scholar 

  57. Schuman P. Prescription of and adherence to antiretroviral therapy among women with AIDS. AIDS Behav. 2001;5:371–8.

    Article  Google Scholar 

  58. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004;16:501–6.

    Article  CAS  PubMed  Google Scholar 

  59. WHO. Phasing Out Stavudine: Progress and Challenges. Supplementary section to the 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, Chapter 9—Guidance on operations and service delivery. www.who.int/hiv/pub/guidelines/arv2013/arv2013supplement_to_chapter09.pdf. Accessed 10 Sept 2015.

  60. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, González-García M, Moltó J, Negredo E, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009;11:103–9.

    PubMed  Google Scholar 

  61. Kryst J, Kawalec P, Pilc A. Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0124279.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403–12.

    Article  CAS  PubMed  Google Scholar 

  63. Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69:422–9.

    Article  CAS  PubMed  Google Scholar 

  64. Johnson MO, Catz SL, Remien RH, Rotheram-Borus MJ, Morin SF, Charlebois E, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS. 2003;17:645–56.

    Article  PubMed  Google Scholar 

  65. Wang X, Wu Z. Factors associated with adherence to antiretroviral therapy among HIV/AIDS patients in rural China. AIDS. 2007;21(Suppl 8):S149–55.

    Article  PubMed  Google Scholar 

  66. Kaptchuk TJ, Miller FG. Placebo effects in medicine. N Engl J Med. 2015;373:8–9.

    Article  CAS  PubMed  Google Scholar 

  67. MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17:86–93.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Brackis-Cott E, Mellins CA, Abrams E, Reval T, Dolezal C. Pediatric HIV medication adherence: the views of medical providers from two primary care programs. J Pediatr Health Care. 2003;17:252–60.

    Article  PubMed  Google Scholar 

  69. Coetzee B, Kagee A, Bland R. Barriers and facilitators to paediatric adherence to antiretroviral therapy in rural South Africa: a multi-stakeholder perspective. AIDS Care. 2015;27:315–21.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

HL, GM, WM, CW, FR, JT conceived and designed the protocol and study. ML, HL, GM, QM acquired the data. HL, GM, JT analyzed the data. HL and GM drafted the manuscript. All authors participated in critically appraising the content and approving the final version.

Funding

This study was funded by the WHO HIV Department, NIAID 1R01AI114310-01, and FIC 1D43TW009532-01.

Author information

Authors and Affiliations

  1. School of Public Health, Shandong University, Jinan, China

    Haochu Li, Gifty Marley & Wei Ma

  2. UNC Project-China, Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Haochu Li, Mellanye Lackey, Qingyan Ma & Joseph D. Tucker

  3. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

    Chongyi Wei

  4. HIV Department, World Health Organization, Geneva, Switzerland

    Françoise Renaud, Marco Vitoria, Rachel Beanland & Meg Doherty

  5. UNC Project-China, Guangdong Provincial Skin Diseases and STI Control, Number 2 Lujing Road, Guangzhou, 510095, China

    Joseph D. Tucker

Authors
  1. Haochu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gifty Marley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chongyi Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mellanye Lackey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qingyan Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Françoise Renaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marco Vitoria
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rachel Beanland
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Meg Doherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Joseph D. Tucker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Haochu Li or Joseph D. Tucker.

Ethics declarations

Conflict of Interest

RB is an affiliated consultant with the World Health Organization and receives remuneration for work related to the topic of this paper. Other authors declare no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 24 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, H., Marley, G., Ma, W. et al. The Role of ARV Associated Adverse Drug Reactions in Influencing Adherence Among HIV-Infected Individuals: A Systematic Review and Qualitative Meta-Synthesis. AIDS Behav 21, 341–351 (2017). https://doi.org/10.1007/s10461-016-1545-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-016-1545-0

Keywords

Search

Navigation